CLDN19 Antibody
-
中文名稱：CLDN19兔多克隆抗體
-
貨號(hào)：CSB-PA571004
-
規(guī)格：￥1100
-
圖片：
-
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA571004(CLDN19 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: ×200)
-
-
其他：
產(chǎn)品詳情
-
Uniprot No.：
-
基因名：CLDN19
-
別名：CLDN19; Claudin-19
-
宿主：Rabbit
-
反應(yīng)種屬：Human,Mouse,Rat
-
免疫原：Synthetic peptide of Human CLDN19
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：Antigen affinity purification
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
-
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA,IHC
-
推薦稀釋比：
Application Recommended Dilution ELISA 1:2000-1:5000 IHC 1:25-1:100 -
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能：Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
-
基因功能參考文獻(xiàn)：
- permeability barriers and affected cell morphology, proliferation, migration, AKT signaling, and gene expression. When claudins are exogenously expressed, ARPE-19 more closely model native RPE. PMID: 27593915
- CLDN19 genetic mutation is responsible for familial magnesium deficiency with hypercalciuria and nephrocalcinosis. PMID: 25410674
- analysis of a novel mutation c.241C>T in exon 2 of CLDN19 in a Chinese patient PMID: 25555744
- Claudin-19, the most abundant claudin in myelin, exhibited no binding to ZO2 protein. PMID: 25712527
- patients with CLDN19 mutations have a high risk of progression to chronic renal disease PMID: 23301036
- Case Reports: novel CLDN19 mutation in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. PMID: 23538362
- The risk of end-stage renal disease in patients with CLDN19 mutations was two times the risk of patients with CLDN16 mutations. Ocular abnormalities were observed only in patients with CLDN19 mutations. PMID: 22422540
- In a patient with consanguineous parents, history of disturbed organization and development of the retina, a diagnosis of Familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by claudin-19 mutation should be considered. PMID: 22734304
- Ocular manifestations and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that may occur in patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis and may indicate CLDN19 mutations. PMID: 21030577
- The identification of CLDN19 mutations in patients with chronic renal failure and severe visual impairment supports the fundamental role of claudin-19 for normal renal tubular function and undisturbed organization and development of the retina. PMID: 17033971
顯示更多
收起更多
-
相關(guān)疾病：Hypomagnesemia 5 (HOMG5)
-
亞細(xì)胞定位：Cell junction, tight junction. Cell membrane; Multi-pass membrane protein.
-
蛋白家族：Claudin family
-
數(shù)據(jù)庫(kù)鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
